# US 2021/0071176 A1 · Compositions for modulating tau expression

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0071176 A1
- Document ID: US20210071176A1
- Status: Published application
- Kind: A1
- Application number: 16/986,770
- Filed: 2020-08-06
- Published: 2021-03-11
- Earliest claimed: 2013-07-19
- Assignees: Biogen MA Inc.
- Applicants: Biogen MA Inc.
- Inventors: Holly Kordasiewicz; Eric E. Swayze; Susan M. Freier; Huynh-Hoa Bui
- Web page: https://patentgrep.com/patent/US20210071176A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61K 31/711: Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07H 21/02: with ribosyl as saccharide radical
- C12N 2310/11: Antisense
- C12N 2310/315: Phosphorothioates
- C12N 2310/3341: 5-Methylcytosine
- C12N 2310/341: Gapmers, i.e. of the type ===---===
- C12N 2310/345: having at least two different backbone modifications
- C12N 2310/346: having a combination of backbone and sugar modifications
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)

## Abstract

Disclosed herein are antisense compounds and methods for decreasing Tau mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate Tau-associated diseases, disorders, and conditions.

## Claims

### Claim 1

(canceled)

### Claim 2

(canceled)

### Claim 3

(canceled)

### Claim 4

(canceled)

### Claim 5

(canceled)

### Claim 6

(canceled)

### Claim 7

(canceled)

### Claim 8

(canceled)

### Claim 9

A compound, comprising a modified oligonucleotide consisting of 12 to 30 linked nucleosides and having a nucleobase sequence comprising at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, or at least 20 consecutive nucleobases of any of the nucleobase sequences of SEQ ID NOs: 20-2565.

### Claim 10

A compound, comprising a modified oligonucleotide consisting of 12 to 30 linked nucleosides and comprising a nucleobase sequence comprising at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, or at least 20 consecutive nucleobases complementary to an equal length portion of nucleobases:
(i) 135783-135980 of SEQ ID NO: 1;
(ii) 135853-135872 of SEQ ID NO: 1;
(iii) 135783-135929 of SEQ ID NO: 1, or
(iv) 135783-135914 of SEQ ID NO: 1.

### Claim 11

(canceled)

### Claim 12

(canceled)

### Claim 13

(canceled)

### Claim 14

(canceled)

### Claim 15 (depends on 9)

The compound of claim 9, consisting of a single-stranded modified oligonucleotide.

### Claim 16 (depends on 9)

The compound of claim 9, wherein at least one internucleoside linkage is a modified internucleoside linkage.

### Claim 17

(canceled)

### Claim 18

(canceled)

### Claim 19

(canceled)

### Claim 20

(canceled)

### Claim 21

(canceled)

### Claim 22

(canceled)

### Claim 23

(canceled)

### Claim 24

(canceled)

### Claim 25

(canceled)

### Claim 26 (depends on 9)

The compound of claim 9, wherein at least one internucleoside linkage is a phosphorothioate linkage and at least one internucleoside linkage is a phosphodiester linkage.

### Claim 27

(canceled)

### Claim 28 (depends on 9)

The compound of claim 9, wherein at least one nucleoside comprises a modified nucleobase.

### Claim 29

(canceled)

### Claim 30 (depends on 9)

The compound of claim 9, wherein at least one nucleoside of the modified oligonucleotide comprises a modified sugar.

### Claim 31 (depends on 30)

The compound of claim 30, wherein the at least one modified sugar is a bicyclic sugar.

### Claim 32

(canceled)

### Claim 33

(canceled)

### Claim 34 (depends on 31)

The compound of claim 31, wherein at least one modified sugar comprises a 2′-O-methoxyethyl group.

### Claim 35

(canceled)

### Claim 36 (depends on 9)

The compound of claim 9, wherein the modified oligonucleotide comprises:
(a) a gap segment consisting of 10 linked deoxynucleosides;
a 5′ wing segment consisting of 5 linked nucleosides; and
a 3′ wing segment consisting of 5 linked nucleosides;
wherein the gap segment is positioned between the 5′ wing segment and the 3′ wing segment and wherein each nucleoside of each wing segment comprises a modified sugar,
(b) a gap segment consisting of 9 linked deoxynucleosides;
a 5′ wing segment consisting of 5 linked nucleosides; and
a 3′ wing segment consisting of 5 linked nucleosides;
wherein the gap segment is positioned between the 5′ wing segment and the 3′ wing segment and wherein each nucleoside of each wing segment comprises a modified sugar;
(c) a gap segment consisting of 7 linked deoxynucleosides;
a 5′ wing segment consisting of 5 linked nucleosides; and
a 3′ wing segment consisting of 6 linked nucleosides;
wherein the gap segment is positioned between the 5′ wing segment and the 3′ wing segment and wherein each nucleoside of each wing segment comprises a modified sugar;
(d) a gap segment consisting of 8 linked deoxynucleosides;
a 5′ wing segment consisting of 5 linked nucleosides; and
a 3′ wing segment consisting of 5 linked nucleosides;
wherein the gap segment is positioned between the 5′ wing segment and the 3′ wing segment and wherein each nucleoside of each wing segment comprises a modified sugar;
(e) a gap segment consisting of 8 linked deoxynucleosides;
a 5′ wing segment consisting of 4 linked nucleosides; and
a 3′ wing segment consisting of 6 linked nucleosides;
wherein the gap segment is positioned between the 5′ wing segment and the 3′ wing segment and wherein each nucleoside of each wing segment comprises a modified sugar; or
(f) a gap segment consisting of 8 linked deoxynucleosides;
a 5′ wing segment consisting of 6 linked nucleosides; and
a 3′ wing segment consisting of 4 linked nucleosides;
wherein the gap segment is positioned between the 5′ wing segment and the 3′ wing segment and wherein each nucleoside of each wing segment comprises a modified sugar.

### Claim 37

(canceled)

### Claim 38

(canceled)

### Claim 39

(canceled)

### Claim 40

(canceled)

### Claim 41

(canceled)

### Claim 42

(canceled)

### Claim 43

(canceled)

### Claim 44 (depends on 9)

The compound of claim 9, wherein the modified oligonucleotide consists of 18 linked nucleosides.

### Claim 45 (depends on 9)

A composition comprising the compound of claim 9 or salt thereof and at least one of a pharmaceutically acceptable carrier or diluent.

### Claim 46 (depends on 9)

A method comprising administering to an animal the compound or composition of claim 9.

### Claim 47 (depends on 46)

The method of claim 46, wherein the animal is a human.

### Claim 48 (depends on 46)

The method of claim 46, wherein administering the compound prevents, treats, ameliorates, or slows progression of a tau associated disease, disorder or condition.

### Claim 49 (depends on 48)

The method of claim 48, wherein the disease, disorder or condition is a Tauopathy, Alzheimer's Disease, Fronto-temporal Dementia (FTD), FTDP-17, Progressive Supranuclear Palsy (PSP), Chronic Traumatic Encephalopathy (CTE), Corticobasal Ganglionic Degeneration (CBD), Epilepsy, or Dravet's Syndrome.

### Claim 50

(canceled)

### Claim 51

(canceled)

### Claim 52

(canceled)

### Claim 53

(canceled)

### Claim 54

(canceled)

### Claim 55

(canceled)

### Claim 56

(canceled)

### Claim 57

A compound consisting of ISIS 613099; ISIS 613361; ISIS 613370; ISIS 623782; or ISIS 623996.

### Claim 58

(canceled)

### Claim 59

(canceled)

### Claim 60

(canceled)

### Claim 61

(canceled)

### Claim 62

A compound consisting of a modified oligonucleotide according to the following formula:
(A) Ges Aeo Teo Aeo Teo Tds Ads Tds mCds mCds Tds Tds Tds Gds Ads Geo mCeo mCes Aes mCe; wherein,
A=an adenine,
mC=a 5′-methylcytosine
G=a guanine,
T=a thymine,
e=a 2′-O-methoxyethyl modified nucleoside,
d=a 2′-deoxynucleoside, and
o=a phosphodiester internucleoside linkage, and
s=a phosphorothioate internucleoside linkage,
(b) Aes mCeo Aeo mCeo Aeo mCds mCds Tds Tds mCds Ads Tds Tds Tds Ads mCeo Teo Ges Tes mCe; wherein,
A=an adenine,
mC=a 5′-methylcytosine
G=a guanine,
T=a thymine,
e=a 2′-O-methoxyethyl modified nucleoside,
d=a 2′-deoxynucleoside, and
o=a phosphodiester internucleoside linkage, and
s=a phosphorothioate internucleoside linkage;
(c) Ges Geo Teo Teo Teo Tds mCds Ads Ads Ads mCds Ads mCds Ads mCds mCeo Teo Tes mCes Ae; wherein,
A=an adenine,
mC=a 5′-methylcytosine
G=a guanine,
T=a thymine,
e=a 2′-O-methoxyethyl modified nucleoside,
d=a 2′-deoxynucleoside,
o=a phosphodiester internucleoside linkage, and
s=a phosphorothioate internucleoside linkage;
(d) mCes mCeo Geo Teo Tes Tds Tds mCds Tds Tds Ads mCds mCds Aeo mCeo mCes mCes Te; wherein,
A=an adenine,
mC=a 5′-methylcytosine
G=a guanine,
T=a thymine,
e=a 2′-O-methoxyethyl modified nucleoside,
d=a 2′-deoxynucleoside,
o=a phosphodiester internucleoside linkage, and
s=a phosphorothioate internucleoside linkage; or
(e) Aes Aeo Teo Teo Tes Gds mCds Tds mCds Tds Tds Ads mCds Teo mCeo mCes mCes Ae; wherein,
A=an adenine,
mC=a 5′-methylcytosine
G=a guanine,
T=a thymine,
e=a 2′-O-methoxyethyl modified nucleoside,
d=a 2′-deoxynucleoside,
o=a phosphodiester internucleoside linkage, and
s=a phosphorothioate internucleoside linkage.

### Claim 63

(canceled)

### Claim 64

(canceled)

### Claim 65

(canceled)

### Claim 66

(canceled)

### Claim 67 (depends on 57)

A composition comprising the compound of claim 57, or salt thereof, and at least one of a pharmaceutically acceptable carrier or diluent.

### Claim 68 (depends on 57)

A method comprising administering to an animal the compound or composition of claim 57.

### Claim 69 (depends on 68)

The method of claim 68, wherein the animal is a human.

### Claim 70 (depends on 67)

The method of claim 67, wherein administering the compound prevents, treats, ameliorates, or slows progression of a tau associated disease, disorder or condition.

### Claim 71 (depends on 70)

The method of claim 70, wherein the disease, disorder or condition is a Tauopathy, Alzheimer's Disease, Fronto-temporal Dementia (FTD), FTDP-17, Progressive Supranuclear Palsy (PSP), Chronic Traumatic Encephalopathy (CTE), Corticobasal Ganglionic Degeneration (CBD), Epilepsy, or Dravet's Syndrome.

### Claim 72

(canceled)

### Claim 73

(canceled)

### Claim 74

(canceled)

### Claim 75

(canceled)

### Claim 76

(canceled)

### Claim 77

(canceled)

### Claim 78

(canceled)

### Claim 79 (depends on 62)

A composition comprising the compound of claim 62, or salt thereof, and at least one of a pharmaceutically acceptable carrier or diluent.

### Claim 80 (depends on 62)

A method comprising administering to a human subject the compound or composition of claim 62, wherein administering the compound prevents, treats, ameliorates, or slows progression of a tau associated disease, disorder or condition in the human subject.
